

## **Can Chiasma describe the MYCAPSSA label?**

MYCAPSSA is a somatostatin analog indicated for the long-term maintenance treatment of acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. Chiasma believes the MYCAPSSA label reflects the results from the positive CHIASMA OPTIMAL pivotal trial. Additionally, the company believes that the label provides health care providers with the necessary information to switch patients with acromegaly on octreotide or lanreotide injectables who may benefit from daily oral therapy.

Dated: June 26, 2020